Prelude Therapeutics Incorporated (PRLD) Stock Forecast
PRLD analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.60 / 5 from 5 analysts
- Price target
- $9.20 average of analyst targets
- Upside to target
- +182.2% from the latest close
- Next earnings
- November 11, 2026 EPS estimate $-0.14
- 52-week range
- $1.19 – $6.63
PRLD analyst ratings
5 analystsNumber of analysts at each rating.
PRLD price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
PRLD earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.14 | −$0.16 | −$0.13 | −$0.26 | +45.1% | 3 |
| Current fiscal year (2026) | −$0.57 | −$0.61 | −$0.54 | −$1.29 | +56.1% | 4 |
| Next fiscal year (2027) | −$0.58 | −$0.79 | −$0.11 | −$0.57 | −2.4% | 4 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
PRLD revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $29.0M | $5.0M | $100.0M | +346.1% | 4 |
| Current fiscal year (2026) | $38.9M | $20.3M | $110.3M | +220.5% | 5 |
| Next fiscal year (2027) | $36.3M | $12.0M | $100.0M | −6.7% | 4 |
PRLD EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
PRLD revenue: reported and forecast
PRLD EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.22 | −$0.14 | −$0.14 | −$0.15 | −$0.14 | −35.2% | 1 up · 0 down |
| Current fiscal year (2026) | −$0.85 | −$0.54 | −$0.54 | −$0.58 | −$0.57 | −33.1% | 1 up · 0 down |
| Next fiscal year (2027) | −$0.94 | −$0.75 | −$0.75 | −$0.55 | −$0.58 | −38.3% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
PRLD earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; PRLD beat in 10 of 12.
What analysts expect from PRLD
5 analysts cover Prelude Therapeutics; their consensus rating is strong buy (4.60 on a 1–5 scale, where 5 is a strong buy). The average price target is $9.20, 182.2% above the latest close of $3.26. Analysts expect earnings of −$0.57 per share for 2026, +56.1% from a year earlier. For 2027 the average estimate is −$0.58 per share on revenue of $36.3 million. Prelude Therapeutics beat the EPS estimate in 10 of the last 12 quarters.
Related: PRLD income statement, PRLD key metrics, PRLD chart. See the PRLD stock overview for the latest quote and news.
PRLD forecast FAQ
What is Prelude Therapeutics's price target?
The average analyst price target for Prelude Therapeutics is $9.20, 182.2% above the latest close of $3.26.
Is Prelude Therapeutics a buy, hold or sell?
Of 5 analysts covering Prelude Therapeutics, 3 rate it a strong buy, 2 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Prelude Therapeutics's EPS forecast?
Analysts forecast −$0.57 per share for 2026 (range −$0.61 to −$0.54); for 2027 the estimate is −$0.58.
What is Prelude Therapeutics's revenue forecast?
The average revenue estimate for 2026 is $38.9 million, growth of 220.5%; for 2027 it is $36.3 million.
When does Prelude Therapeutics report earnings?
Prelude Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 11, 2026 before the market opens; the EPS estimate is $-0.14.
Does Prelude Therapeutics usually beat earnings estimates?
Prelude Therapeutics reported EPS at or above the analyst estimate in 10 of the last 12 quarters.